In the ALEX phase 3 clinical trial alectinib, a second-generation ALK-TKI was compared to crizotinib in first-line treatment of metastatic ALK-positive NSCLC showing a longer PFS and brain control [24]. This evidence concerns the gene ALK and non-small cell lung carcinoma.